Digene Corporation develops, manufactures and markets proprietary gene-based testing systems for the screening, monitoring and diagnosis of human diseases. The company’s primary focus is in women’s cancers and infectious diseases.

Digene's core focus has been on two major women's health issues - cervical cancer and STDs. Cervical cancer is the second most common cancer among women worldwide. Virtually all cases of cervical cancer are preventable if detected in the pre-cancerous stage.

Digene has set up its European headquarters in Geneva. Last year the Group posted a turnover of 50 million dollars and has budgeted a turnover this year of 65 million dollars.